LINCOMYCIN HYDROCHLORIDE


Trade Names	LINCOCIN LINCOMYCIN LINCOMYCIN HCL LINCOMYCIN HYDROCHLORIDE
Synonyms	Albiotic Lincocin Lincolnensin hydrochloride Lincolnensin hydrochloride monohydrate Lincomix Lincomycin (as hydrochloride) Lincomycin hcl Lincomycin hydrochloride Lincomycin hydrochloride anhdrous Lincomycin hydrochloride hydrate Lincomycin hydrochloride monohydrate Lincomycin hydrochloride usp NSC-70731 NSC-757092
Status
Molecule Category	Salt-form
UNII	M6T05Z2B68
Parent Compound:	LINCOMYCIN


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	LFZGYTBWUHCAKF-DCNJEFSFSA-N
Smiles	CCC[C@@H]1C[C@@H](C(=O)N[C@@H]([C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)[C@@H](C)O)N(C)C1.Cl.O
InChI	InChI=1S/C18H34N2O6S.ClH.H2O/c1-5-6-10-7-11(20(3)8-10)17(25)19-12(9(2)21)16-14(23)13(22)15(24)18(26-16)27-4;;/h9-16,18,21-24H,5-8H2,1-4H3,(H,19,25);1H;1H2/t9-,10-,11+,12-,13+,14-,15-,16-,18-;;/m1../s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C18H37ClN2O7S
Molecular Weight	461.02
AlogP	-0.86
Hydrogen Bond Acceptor	8.0
Hydrogen Bond Donor	5.0
Number of Rotational Bond	7.0
Polar Surface Area	122.49
Molecular species	NEUTRAL
Aromatic Rings	0.0
Heavy Atoms	27.0

Bioactivity

Mechanism of Action	Action	Reference
70S ribosome inhibitor	INHIBITOR	PubMed PubMed

Cross References

Resources	Reference
ChEBI	6472
ChEMBL	CHEMBL3989551
FDA SRS	M6T05Z2B68
KEGG	C14002
PubChem	71476
SureChEMBL	SCHEMBL192963
ZINC	ZINC03982483

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).